{
  "ticker": "JNJ",
  "date": "2025-10-13",
  "lookback_days": 14,
  "fetched_at": "2026-02-13T12:02:31.802467",
  "source": "alpha_vantage",
  "article_count": 50,
  "articles": [
    {
      "title": "Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing",
      "summary": "Cyndeo Wealth Partners recently purchased 40,238 shares of Johnson & Johnson (JNJ) valued at approximately $6.89 million, increasing their total holding to $19.25 million. This investment highlights the firm's conviction in JNJ, which has seen strong stock performance, outperforming the S&P 500, despite ongoing litigation risks. The article suggests JNJ could be an attractive option for value-oriented investors due to its dividend yield and P/E ratio.",
      "url": "https://www.fool.com/coverage/filings/2025/10/13/big-money-move-investment-manager-buys-usd6-9-million-worth-of-johnson-and-johnson-shares-according-to-recent-filing/?source=financialcontent&utm_source=financialcontent&utm_medium=feed&utm_campaign=article&referring_guid=fe29ae6a-010a-42d1-8d73-4395676cbad5",
      "source": "The Motley Fool",
      "published": "20251013T224700",
      "overall_sentiment_score": 0.18855,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.45357,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing",
      "summary": "Cyndeo Wealth Partners, LLC reported purchasing 40,238 shares of Johnson & Johnson (JNJ) for an estimated $6.89 million during Q3 2025. This acquisition increased their total JNJ holding to 103,832 shares, valued at $19.25 million, representing 1.07% of their assets under management. The article highlights J&J's strong performance, attractive dividend yield, and relatively affordable valuation despite ongoing litigation risks.",
      "url": "https://www.fool.com/coverage/filings/2025/10/13/big-money-move-investment-manager-buys-usd6-9-million-worth-of-johnson-and-johnson-shares-according-to-recent-filing/",
      "source": "The Motley Fool",
      "published": "20251013T224700",
      "overall_sentiment_score": 0.178629,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.34101,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "J&J says CareFirst distorts the law in US antitrust case over Stelara - MLex",
      "summary": "Johnson & Johnson and Janssen Biotech have filed a reply brief in their US antitrust case concerning the drug Stelara, asserting that CareFirst's opposition distorts both the relevant law and the factual record. J&J argues that CareFirst offers mere speculation rather than concrete evidence to support its claims of deceptive intent related to alleged omissions or misrepresentations to the Patent and Trademark Office. The company requests a judgment against CareFirst in this ongoing legal dispute.",
      "url": "https://www.mlex.com/mlex/antitrust/articles/2398972/j-j-says-carefirst-distorts-the-law-in-us-antitrust-case-over-stelara",
      "source": "MLex",
      "published": "20251013T195300",
      "overall_sentiment_score": -0.236117,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.212627,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 1.0
    },
    {
      "title": "Why I’m Not Buying This “Perfect” Dividend Stock (Yet)",
      "summary": "This article analyzes Johnson & Johnson (JNJ) as a potential dividend stock, evaluating its business, financials, and current price. The author provides a qualitative score highlighting JNJ's strong position in the non-cyclical healthcare sector with its diverse product offerings in Innovative Medicine and MedTech. The conclusion regarding the investment decision is withheld behind a membership paywall.",
      "url": "https://medium.datadriveninvestor.com/why-im-not-buying-this-perfect-dividend-stock-yet-d5b283c9d213",
      "source": "DataDrivenInvestor",
      "published": "20251013T164354",
      "overall_sentiment_score": 0.247131,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.218386,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings as Cancer Therapy Gets Warning Label - TipRanks",
      "summary": "Johnson & Johnson (JNJ) stock saw a decline ahead of its Q3 earnings report after the FDA issued a new warning label for its cancer therapy, Carvykti, citing a potential fatal side effect. Despite this, the FDA maintains the overall benefit of the medication outweighs the risks. Analysts anticipate JNJ to report strong revenue and EPS for Q3, and the stock currently holds a \"Moderate Buy\" consensus rating from Wall Street analysts.",
      "url": "https://www.tipranks.com/news/johnson-johnsons-stock-jnj-falters-ahead-of-earnings-as-cancer-therapy-gets-warning-label",
      "source": "TipRanks",
      "published": "20251013T155630",
      "overall_sentiment_score": -0.268582,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.260614,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 1.0
    },
    {
      "title": "FDA adds warning to label of J&J, Legend's Carvykti for potentially fatal intestinal disorder - Fierce Pharma",
      "summary": "The FDA has added a boxed warning to the label of Johnson & Johnson and Legend Biotech's CAR-T therapy Carvykti, citing the risk of immune effector cell-associated enterocolitis (IEC-EC), a potentially fatal intestinal disorder. This condition, which can lead to gut perforation and sepsis, has been observed in 1% of patients treated with Carvykti in clinical trials and post-marketing. Despite the new warning, the FDA maintains that the benefits of Carvykti, which has shown significant progression-free and overall survival benefits in multiple myeloma patients, continue to outweigh its potential risks.",
      "url": "https://www.fiercepharma.com/pharma/fda-adds-warning-label-jjs-carvykti-potentially-fatal-intestinal-disorder",
      "source": "Fierce Pharma",
      "published": "20251013T151651",
      "overall_sentiment_score": -0.143322,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": -0.22106,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson Stock Setting New Highs Ahead of Earnings – What To Expect - AskTraders.com",
      "summary": "Johnson & Johnson (JNJ) is approaching its Q3 2025 earnings release amidst legal challenges from talc litigation and strategic portfolio reshaping. Analysts expect an EPS of $2.76 for Q3 2025. Despite legal headwinds, strategic moves like the acquisition of Intra-Cellular Therapies and the Kenvue spin-off aim to bolster the company's financial performance and focus on higher-margin sectors.",
      "url": "https://www.asktraders.com/analysis/johnson-johnson-earnings-on-deck-navigating-legal-storms-and-strategic-shifts/",
      "source": "AskTraders.com",
      "published": "20251013T140524",
      "overall_sentiment_score": 0.124443,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.135526,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 1.0
    },
    {
      "title": "Aberdeen Group plc Has $414.20 Million Holdings in Johnson & Johnson $JNJ",
      "summary": "Aberdeen Group plc increased its stake in Johnson & Johnson (NYSE:JNJ) by 0.8% in the second quarter, making JNJ its 18th biggest position with holdings valued at $414.20 million. Other institutional investors also adjusted their positions, and the article provides details on JNJ's recent stock performance, earnings, and dividend announcements. Analysts have issued new price targets, with some reiterating \"outperform\" ratings.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-has-41420-million-holdings-in-johnson-johnson-jnj-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T100816",
      "overall_sentiment_score": 0.348028,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.339265,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "J&J in talks to acquire Protagonist Therapeutics - Pharmaceutical Technology",
      "summary": "Johnson & Johnson (J&J) is reportedly in discussions to acquire Protagonist Therapeutics, a move that would expand J&J's cancer and immune drug portfolio. The acquisition would grant J&J access to Protagonist’s rusfertide, a promising drug in late-stage trials for polycythaemia vera, and enhance their existing collaboration on an oral immune disease treatment. This strategic acquisition would help J&J mitigate potential sales losses from patent expirations for its immune-disease drug Stelara.",
      "url": "https://www.pharmaceutical-technology.com/news/jj-protagonist-therapeutics/",
      "source": "Pharmaceutical Technology",
      "published": "20251013T094859",
      "overall_sentiment_score": 0.28709,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.427563,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Drucker Wealth 3.0 LLC Has $2.10 Million Stake in Johnson & Johnson $JNJ",
      "summary": "Drucker Wealth 3.0 LLC significantly increased its stake in Johnson & Johnson (JNJ) by 121%, now holding 13,419 shares valued at $2.1 million. The article also details insider stock sales, particularly by EVP Jennifer L. Taubert, and highlights that Wall Street analysts maintain a \"Moderate Buy\" rating for JNJ with a consensus price target of $192.94. Key financial metrics and recent dividend information for Johnson & Johnson are provided as well.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-drucker-wealth-30-llc-has-210-million-stake-in-johnson-johnson-jnj-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T085026",
      "overall_sentiment_score": 0.326776,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.313022,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy - EconoTimes",
      "summary": "The FDA has issued a black box warning for Johnson & Johnson and Legend Biotech's multiple myeloma therapy, Carvykti, due to a rare but potentially fatal gastrointestinal condition called immune effector cell–associated enterocolitis (IEC-EC). Despite this new warning, the FDA maintains that the overall benefits of Carvykti still outweigh the risks for its approved uses. Johnson & Johnson has reiterated the therapy's positive clinical profile, noting its effectiveness and durable responses in over 8,500 patients.",
      "url": "http://www.econotimes.com/FDA-Adds-Fatal-Risk-Warning-to-JJ-and-Legend-Biotechs-Carvykti-Cancer-Therapy-1723032",
      "source": "EconoTimes",
      "published": "20251013T024044",
      "overall_sentiment_score": -0.287946,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.28463,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 1.0
    },
    {
      "title": "Is There Still Opportunity in J&J Shares After 32% Rally in 2025? - simplywall.st",
      "summary": "This article analyzes Johnson & Johnson (J&J) stock after a significant rally in 2025, exploring whether it remains a good investment. Using Discounted Cash Flow (DCF) and Price-to-Earnings (PE) ratio analyses, the article suggests that J&J shares are undervalued. It also introduces \"Narratives\" as a personalized approach for investors to evaluate the stock based on their own forecasts and market context.",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/is-there-still-opportunity-in-jj-shares-after-32-rally-in-20",
      "source": "simplywall.st",
      "published": "20251012T205400",
      "overall_sentiment_score": 0.179293,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.331382,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal - The Motley Fool",
      "summary": "Douglas Lane & Associates increased its holdings in Johnson & Johnson by $6 million, purchasing an additional 34,948 shares ahead of the company's Q3 earnings report and potential biotech acquisition talks. This move signals confidence as J&J has consistently outperformed earnings estimates and is reportedly negotiating to acquire Protagonist Therapeutics, which could boost its immunology pipeline. J&J's shares have risen 18% over the past year, outperforming the S&P 500.",
      "url": "https://www.fool.com/coverage/filings/2025/10/12/douglas-lane-adds-usd6-million-in-j-and-j-stock-ahead-of-earnings-and-possible-biotech-deal/?source=globeandmail&utm_source=globeandmail&utm_medium=feed&utm_campaign=article&referring_guid=805d91aa-6155-49db-9005-e309d410df88",
      "source": "The Motley Fool",
      "published": "20251012T191454",
      "overall_sentiment_score": 0.246345,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.406703,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Johnson & Johnson Stock Price Forecast - JNJ Steadies at $190.72 as $7B Protagonist Deal and $10B Talc Risks",
      "summary": "Johnson & Johnson (JNJ) stock is trading at $190.72, near its 52-week high, as investors weigh strong Q2 2025 earnings and a potential $7 billion acquisition of Protagonist Therapeutics against significant talc litigation risks and biosimilar competition for key drugs like Stelara. The company's innovative medicines and MedTech segments show growth, while its defensive nature and dividend streak continue to attract institutional support, leading to a \"Hold with a medium-term bullish bias\" verdict.",
      "url": "https://www.tradingnews.com/news/jhonson-and-jonson-stock-price-forecast-jnj-steadies-at-190-usd-as-7b-usd-progaonist",
      "source": "TradingNEWS",
      "published": "20251012T183841",
      "overall_sentiment_score": 0.133198,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.235454,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "FDA approves labeling changes for Janssen’s Carvykti - The Pharma Letter",
      "summary": "The FDA has approved labeling changes for Janssen's CAR-T cell therapy Carvykti due to reports of immune effector cell-associated enterocolitis (IEC-EC), a serious and potentially fatal adverse effect. These reports came from both clinical trials and post-marketing data, with patients experiencing severe gastrointestinal issues weeks to months after infusion. Despite these safety concerns, Carvykti generated $439 million in sales for J&J in Q2 2025, an 18% increase quarter-over-quarter.",
      "url": "https://www.thepharmaletter.com/biotechnology/fda-approves-labeling-changes-for-janssen-s-carvykti",
      "source": "The Pharma Letter",
      "published": "20251013T100422",
      "overall_sentiment_score": -0.24717,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.216625,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 0.995399
    },
    {
      "title": "Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal - The Motley Fool",
      "summary": "Douglas Lane & Associates increased its holdings in Johnson & Johnson by $6 million, adding 34,948 shares ahead of the company's Q3 earnings report. This move signals confidence as J&J has consistently exceeded earnings estimates and is reportedly in talks to acquire Protagonist Therapeutics, which could bolster its immunology pipeline. Johnson & Johnson's stock has outperformed the S&P 500 over the past year.",
      "url": "https://www.fool.com/coverage/filings/2025/10/12/douglas-lane-adds-usd6-million-in-j-and-j-stock-ahead-of-earnings-and-possible-biotech-deal/",
      "source": "The Motley Fool",
      "published": "20251012T191454",
      "overall_sentiment_score": 0.160742,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.31608,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.980726
    },
    {
      "title": "Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale (NASDAQ:PTGX) - Seeking Alpha",
      "summary": "Protagonist Therapeutics (PTGX) saw a significant stock surge following Johnson & Johnson's (JNJ) reported acquisition interest, driven by J&J's need to counteract declining Stelara sales. PTGX's lead assets, Icotrokinra and Rusfertide, hold a combined peak sales potential of $7 billion, making them attractive to JNJ's immunology pipeline. A deal exceeding PTGX's current $4 billion market capitalization, ideally over $5 billion, would be necessary to justify existing share prices and provide further upside for investors.",
      "url": "https://seekingalpha.com/article/4829502-why-johnson-and-johnson-is-eyeing-protagonist-therapeutics-the-rationale",
      "source": "Seeking Alpha",
      "published": "20251013T140905",
      "overall_sentiment_score": 0.279682,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.295957,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.957821
    },
    {
      "title": "United States Advanced Surgical Equipment Market Projected - openPR.com",
      "summary": "The United States Advanced Surgical Equipment Market is projected to grow at a 9.6% CAGR, reaching USD 48.5 billion by 2030, driven by technological innovations and increasing demand for minimally invasive procedures. Key industry players include Medtronic PLC, Johnson & Johnson, and Intuitive Surgical Inc., which are continuously developing new robotic surgical systems and advanced energy devices. The market's expansion is further fueled by the integration of AI in surgical systems and the modernization of healthcare infrastructure.",
      "url": "https://www.openpr.com/news/4221064/united-states-advanced-surgical-equipment-market-projected",
      "source": "openPR.com",
      "published": "20251013T130035",
      "overall_sentiment_score": 0.273483,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.322361,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.947558
    },
    {
      "title": "J&J in talks to acquire Protagonist Therapeutics - Yahoo Finance",
      "summary": "Johnson & Johnson (J&J) is reportedly in discussions to acquire Protagonist Therapeutics, a move expected to significantly expand J&J's cancer and immune drug portfolio. J&J already holds a 4% stake in Protagonist and collaborates on an oral immune disease treatment. The acquisition would also give J&J access to Protagonist's promising drug rusfertide, currently in late-stage trials for a rare blood cancer.",
      "url": "https://finance.yahoo.com/news/j-j-talks-acquire-protagonist-104635759.html",
      "source": "Yahoo Finance",
      "published": "20251013T104635",
      "overall_sentiment_score": 0.31468,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.302792,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.942328
    },
    {
      "title": "Street View: Protagonist's 'main character' energy draws J&J to potential takeover talks - TradingView",
      "summary": "Johnson & Johnson is reportedly in discussions to acquire Protagonist Therapeutics, with analysts highlighting Protagonist's strong pipeline and undervalued stock. Brokerages largely rate PTGX as \"buy\" or higher, citing its oral peptide technology platform and the potential impact of its immunology drug, icotrokinra, developed in partnership with J&J. This potential acquisition aligns with J&J's focus on its Immunology and Oncology franchises.",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_L3N3VU0XL:0-street-view-protagonist-s-main-character-energy-draws-j-j-to-potential-takeover-talks/",
      "source": "TradingView",
      "published": "20251013T140501",
      "overall_sentiment_score": 0.391682,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.389284,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 0.907107
    },
    {
      "title": "Johnson & Johnson Stock To Acquire Protagonist? It'd Be A Good Deal To Make (NYSE:JNJ) - Seeking Alpha",
      "summary": "Johnson & Johnson Stock To Acquire Protagonist? It'd Be A Good Deal To Make (NYSE:JNJ)",
      "url": "https://seekingalpha.com/article/4829332-johnson-and-johnson-to-acquire-protagonist-itd-be-good-deal-to-make",
      "source": "Seeking Alpha",
      "published": "20251012T130000",
      "overall_sentiment_score": 0.1937,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.304098,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.903033
    },
    {
      "title": "Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ) - Seeking Alpha",
      "summary": "Protagonist Therapeutics (PTGX) stock dropped 5% following a report suggesting that the potential acquisition price from Johnson & Johnson (JNJ) might be lower than Protagonist's current share price. Blackstone is rumored to be collaborating with Johnson & Johnson on this deal.",
      "url": "https://seekingalpha.com/news/4503679-protagonist-therapeutics-falls-amid-a-report-jj-deal-price-may-be-lower",
      "source": "Seeking Alpha",
      "published": "20251013T172423",
      "overall_sentiment_score": -0.095444,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": -0.202165,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 0.742495
    },
    {
      "title": "Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Yahoo Finance",
      "summary": "Protagonist Therapeutics (PTGX) stock gained 30% after a report suggested Johnson & Johnson (JNJ) is interested in acquiring the company. J&J's interest appears driven by the need to offset declining Stelara sales and expand its immunology and hematology pipelines. This potential acquisition highlights a continuing trend of major pharmaceutical companies seeking strategic assets from smaller biotechs despite broader economic concerns.",
      "url": "https://finance.yahoo.com/news/protagonist-therapeutics-stock-gains-30-185000996.html",
      "source": "Yahoo Finance",
      "published": "20251013T185000",
      "overall_sentiment_score": 0.258291,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.332038,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.739947
    },
    {
      "title": "Johnson & Johnson Eyes Protagonist Therapeutics Acquisition, PTGX Drops",
      "summary": "Protagonist Therapeutics (PTGX) shares dropped 5% on rumors of a lower-than-market-value acquisition by Johnson & Johnson, potentially in partnership with Blackstone, with an anticipated offer around $75 per share. Despite strong financial health and revenue growth, concerns arise from high valuation multiples and significant insider selling. The company's innovative pipeline and robust balance sheet contrast with its current profitability challenges and elevated P/E ratio.",
      "url": "https://www.gurufocus.com/news/3140920/johnson-johnson-eyes-protagonist-therapeutics-acquisition-ptgx-drops",
      "source": "GuruFocus",
      "published": "20251013T181331",
      "overall_sentiment_score": 0.343705,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.32639,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.718597
    },
    {
      "title": "Earnings week ahead: JPM, C, WFC, GS, MS, WFC, TSM, JNJ, SLB, and more (NYSE:JNJ) - Seeking Alpha",
      "summary": "The upcoming week in mid-October marks a significant period for earnings reports, featuring major companies across finance, healthcare, technology, and consumer goods. Key financial institutions like JPMorgan Chase, Citigroup, Wells Fargo, Goldman Sachs, and Morgan Stanley are set to announce, alongside Johnson & Johnson, Taiwan Semiconductor Manufacturing Company, and Schlumberger. Investors will be scrutinizing these reports for insights into the health of various sectors, including banking, AI chip demand, and the oilfield services market.",
      "url": "https://seekingalpha.com/news/4503333-earnings-week-ahead-jpm-c-wfc-gs-ms-wfc-tsm-jnj-slb-and-more",
      "source": "Seeking Alpha",
      "published": "20251012T120026",
      "overall_sentiment_score": 0.100574,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.113685,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.64584
    },
    {
      "title": "Vision Care: Global Market Report 2025 | Leading Vision Care Companies Spotlighted: Profiles of EssilorLuxottica, Alcon, and More",
      "summary": "This report details the global vision care market for 2025, highlighting key opportunities in product enhancements across eyeglass lenses, contact lenses, and IOLs. It forecasts market growth driven by technological advancements and strategic developments by leading companies like EssilorLuxottica and Alcon, projecting market values of $75.1 billion in 2025 and $98 billion by 2030 with a CAGR of 5.5%. The study provides a comprehensive regional analysis, market dynamics, regulatory landscape, and profiles of major players.",
      "url": "https://www.globenewswire.com/fr/news-release/2025/10/13/3165605/0/en/Vision-Care-Global-Market-Report-2025-Leading-Vision-Care-Companies-Spotlighted-Profiles-of-EssilorLuxottica-Alcon-and-More.html?utm_co=",
      "source": "GlobeNewswire",
      "published": "20251013T164140",
      "overall_sentiment_score": 0.201145,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.247994,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.615409
    },
    {
      "title": "Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? - The Globe and Mail",
      "summary": "Pharmaceutical stocks recently experienced their best weekly gain in two decades, driven by a potential avoidance of tariffs as companies like Pfizer, Johnson & Johnson, Merck, and Eli Lilly committed to increased U.S. manufacturing. An exchange-traded fund like the VanEck Pharmaceutical ETF is presented as a diversified and low-cost way to invest in these major drugmakers. The article suggests that if policy changes lead to cheaper drugs and more domestic production, it could benefit both consumers and pharmaceutical investors.",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRK-N/pressreleases/35403793/drug-stocks-just-had-their-best-week-in-2-decades-should-you-invest/",
      "source": "The Globe and Mail",
      "published": "20251013T101539",
      "overall_sentiment_score": 0.354356,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.345708,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.613847
    },
    {
      "title": "Endometriosis Drugs Market to expand robustly in 2025 | AbbVie, Pfizer, Bayer AG",
      "summary": "The global Endometriosis Drugs Market is projected to expand significantly between 2025 and 2032, driven by increased focus on women's health and personalized medicine. Key players like AbbVie, Pfizer, and Bayer AG are leading the market, which is segmented by hormonal and non-hormonal therapies, pain management drugs, and surgical treatments, and distributed through various pharmacy channels. The market is expected to grow from USD 2.8 billion in 2025 to USD 4 billion by 2032, achieving a CAGR of 5.2%.",
      "url": "https://www.newstrail.com/endometriosis-drugs-market-to-expand-robustly-in-2025-abbvie-pfizer-bayer-ag/",
      "source": "newstrail.com",
      "published": "20251013T100857",
      "overall_sentiment_score": 0.338758,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.305732,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.536563
    },
    {
      "title": "2025 Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Evolution: Data-Driven Insights and Forecast to ... - WhaTech",
      "summary": "The Hypertrophic Cardiomyopathy (HCM) therapeutics market is projected to grow from $1.34 billion in 2024 to $1.56 billion by 2029, driven by advancements in diagnostics, increasing awareness, and the rising prevalence of cardiovascular diseases. Key trends include specialized treatments, personalized medicine, and product innovation, with North America leading the market and Asia-Pacific showing the fastest growth. Major companies like Bristol Myers Squibb are introducing novel treatments such as Camzyos to address the pathophysiology of obstructive HCM.",
      "url": "https://www.whatech.com/og/markets-research/medical/992735-2025-hypertrophic-cardiomyopathy-hcm-therapeutics-market-evolution-data-driven-insights-and-forecast-to-2034.html",
      "source": "WhaTech",
      "published": "20251013T121618",
      "overall_sentiment_score": 0.179702,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.134039,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.536215
    },
    {
      "title": "What to Watch in the Day Ahead - Tuesday, October 14",
      "summary": "The article outlines key events for October 14, focusing on the kickoff of Q3 earnings season with major U.S. banks like JPMorgan Chase, Goldman Sachs, Wells Fargo, and Citigroup expected to report higher profits driven by investment banking. It also highlights economic data releases, Federal Reserve speeches, and earnings reports from companies like Johnson & Johnson, BlackRock, and Domino's Pizza, alongside financial leaders' meetings in Washington D.C.",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_L6N3VU0P9:0-what-to-watch-in-the-day-ahead-tuesday-october-14/",
      "source": "TradingView",
      "published": "20251013T183012",
      "overall_sentiment_score": 0.306611,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.14998,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.528214
    },
    {
      "title": "Traders Buy High Volume of Kenvue Call Options (NYSE:KVUE)",
      "summary": "Kenvue Inc. (NYSE:KVUE) experienced unusual options trading activity with investors acquiring 117,463 call options, a 52% increase from average. The stock traded down $0.49, closing at $16.17, despite positive earnings results and an increased quarterly dividend. Institutional investors hold a significant portion of the company's shares, and analysts have a \"Hold\" rating with a consensus target price of $21.18.",
      "url": "https://www.marketbeat.com/instant-alerts/traders-buy-high-volume-of-kenvue-call-options-nysekvue-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T190350",
      "overall_sentiment_score": -0.072803,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.207854,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.523168
    },
    {
      "title": "United States Valley Fever Market to Reach USD 1.98 Billion - openPR.com",
      "summary": "The United States Valley Fever Market is projected to reach USD 1.98 billion by 2033, driven by increasing disease incidence, climate change, and improved diagnostics. Key players like Pfizer, Merck, and Novartis are leading in developing treatments and diagnostics. The market is segmented by infection type, drug type, administration route, and distribution channel, with significant recent industry developments in both the US and Japan.",
      "url": "https://www.openpr.com/news/4220969/united-states-valley-fever-market-to-reach-usd-1-98-billion",
      "source": "openPR.com",
      "published": "20251013T122702",
      "overall_sentiment_score": 0.286591,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.220862,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.516077
    },
    {
      "title": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
      "summary": "AstraZeneca has reached an agreement with the Trump administration to lower drug prices in the U.S., aligning with the Most Favored Nation pricing proposal and offering significant discounts, similar to a prior deal with Pfizer. In exchange, AstraZeneca receives a three-year exemption from import tariffs on pharmaceutical ingredients and commits to a $50 billion investment in expanding its U.S. manufacturing and R&D footprint. This move, along with similar commitments from other major pharma companies, signals a potential turning point in addressing drug pricing and tariff concerns within the pharmaceutical industry.",
      "url": "https://www.tradingview.com/news/zacks:fbc7cfa82094b:0-azn-strikes-drug-pricing-deal-with-trump-gets-3-year-tariff-reprieve/",
      "source": "TradingView",
      "published": "20251013T174000",
      "overall_sentiment_score": 0.326415,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.34412,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.508648
    },
    {
      "title": "Dr Reddy’s, Zydus recall drugs in US over manufacturing issues: USFDA - Daily Excelsior",
      "summary": "Indian drug makers Dr Reddy's Laboratories and Zydus Lifesciences are recalling certain products in the US due to manufacturing issues. Dr Reddy's is recalling 571 vials of Succinylcholine Chloride Injection due to out-of-specification results, while Zydus is recalling over 1,500 boxes of Entecavir tablets due to failed impurity specifications. The recalls are classified as Class II, indicating potential temporary or reversible health consequences.",
      "url": "https://www.dailyexcelsior.com/dr-reddys-zydus-recall-drugs-in-us-over-manufacturing-issues-usfda/",
      "source": "Daily Excelsior",
      "published": "20251012T230525",
      "overall_sentiment_score": -0.201159,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.16808,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 0.467332
    },
    {
      "title": "Broadridge's Distributed Ledger Repo Platform Processes $339 Billion in Average Daily Trade Volumes in September - StreetInsider",
      "summary": "Broadridge announced record activity on its Distributed Ledger Repo (DLR) platform, processing $339 billion in average daily repo transactions in September. This represents a 21% increase over August and a 650% year-over-year increase, signaling rapid adoption of tokenized settlement. Broadridge's DLR platform is highlighted as the world's largest institutional platform for settling tokenized real assets, leveraging tokenization and smart contracts to enhance efficiency in the global repo market.",
      "url": "https://www.streetinsider.com/PRNewswire/Broadridges+Distributed+Ledger+Repo+Platform+Processes+%24339+Billion+in+Average+Daily+Trade+Volumes+in+September/25446286.html",
      "source": "StreetInsider",
      "published": "20251013T060114",
      "overall_sentiment_score": 0.199063,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.104494,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.44559
    },
    {
      "title": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
      "summary": "AstraZeneca has reached a drug pricing agreement with the Trump administration, committing to reduce prescription drug prices to match those in comparable developed countries. In exchange, AstraZeneca will receive a three-year exemption from import tariffs on pharmaceutical ingredients, conditional on expanding its domestic manufacturing operations, including a new $4.5 billion facility in Virginia. This deal, similar to one with Pfizer, is seen as a turning point to ease regulatory and pricing pressures on the pharmaceutical industry, encouraging more U.S. investments from other large-cap pharma companies such as AbbVie and Eli Lilly.",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/AZN/pressreleases/35412822/azn-strikes-drug-pricing-deal-with-trump-gets-3-year-tariff-reprieve/",
      "source": "The Globe and Mail",
      "published": "20251013T195056",
      "overall_sentiment_score": 0.286267,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.241109,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.439522
    },
    {
      "title": "Should Omvoh’s Clinical Success and Earnings Optimism Prompt Action from Eli Lilly (LLY) Investors?",
      "summary": "Eli Lilly recently announced strong four-year clinical trial results for its ulcerative colitis therapy Omvoh, demonstrating sustained efficacy and a favorable safety profile. This positive clinical news, combined with optimism for upcoming robust quarterly earnings driven by Mounjaro and Zepbound sales, reinforces Eli Lilly's reputation for innovation. Investors are encouraged to consider these developments as they impact the company's growth trajectory and investment narrative, despite potential risks from drug pricing pressures.",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/should-omvohs-clinical-success-and-earnings-optimism-prompt",
      "source": "simplywall.st",
      "published": "20251012T211904",
      "overall_sentiment_score": 0.250925,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.136937,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.438193
    },
    {
      "title": "Kenvue Inc. $KVUE Holdings Raised by Blair William & Co. IL",
      "summary": "Blair William & Co. IL significantly increased its stake in Kenvue Inc. (KVUE) during the second quarter, now holding 206,387 shares valued at $4.32 million. Kenvue reported Q2 earnings per share of $0.29, slightly above estimates, despite a 4.0% year-over-year revenue decline. The company also announced an increased quarterly dividend of $0.2075 per share, yielding 5.0% annually.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-kenvue-inc-kvue-holdings-raised-by-blair-william-co-il-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T101340",
      "overall_sentiment_score": 0.178274,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.107856,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.434575
    },
    {
      "title": "Rep. Val T. Hoyle Sells Kenvue Inc. (NYSE:KVUE) Shares",
      "summary": "Representative Val T. Hoyle sold between $1,001 and $15,000 worth of Kenvue Inc. (NYSE:KVUE) shares on September 23rd, as disclosed in an October 10th filing. Kenvue's stock is currently trading at $16.68, down 1.0%, with a market capitalization of $32 billion, and the company recently increased its quarterly dividend to $0.2075. Analysts have a consensus \"Hold\" rating on Kenvue with a target price of $21.18, despite recent adjustments from firms like Rothschild & Co Redburn and JPMorgan Chase & Co.",
      "url": "https://www.marketbeat.com/instant-alerts/rep-val-t-hoyle-sells-kenvue-inc-nysekvue-shares-2025-10-11/",
      "source": "MarketBeat",
      "published": "20251012T150320",
      "overall_sentiment_score": 0.063597,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.103792,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.419639
    },
    {
      "title": "NorthRock Partners LLC Boosts Stake in AbbVie Inc. $ABBV - MarketBeat",
      "summary": "NorthRock Partners LLC has increased its stake in AbbVie Inc. by 2.3%, bringing its total holdings to 76,797 shares valued at $14.25 million. This increase comes as AbbVie reported quarterly earnings of $2.97 per share, missing expectations, but exceeded revenue predictions with $15.42 billion. The company also announced a quarterly dividend of $1.64 per share, representing an annualized yield of 2.8%.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-northrock-partners-llc-boosts-stake-in-abbvie-inc-abbv-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T095442",
      "overall_sentiment_score": 0.12651,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.133498,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.418265
    },
    {
      "title": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - Yahoo Finance",
      "summary": "AstraZeneca has reached an agreement with the Trump administration to lower drug prices in the U.S. by matching prices in other developed countries, offering discounts of up to 80% through direct-to-consumer channels and TrumpRx.gov. In exchange, AstraZeneca receives a three-year exemption from import tariffs on pharmaceutical ingredients and commits to investing $50 billion over five years to expand its U.S. manufacturing and R&D operations. This deal, similar to one with Pfizer, signals a potential shift in regulatory and pricing pressures for the pharmaceutical industry.",
      "url": "https://finance.yahoo.com/news/azn-strikes-drug-pricing-deal-174000433.html",
      "source": "Yahoo Finance",
      "published": "20251013T174000",
      "overall_sentiment_score": 0.528132,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.428692,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 0.417913
    },
    {
      "title": "Yousif Capital Management LLC Sells 5,410 Shares of AbbVie Inc. $ABBV",
      "summary": "Yousif Capital Management LLC decreased its stake in AbbVie Inc. by 2.2%, selling 5,410 shares and now holding 237,788 shares valued at $44 million. AbbVie recently announced a quarterly dividend of $1.64 per share, representing an annualized payout of $6.56 and a 2.8% yield, despite reporting earnings of $2.97 per share, missing analyst expectations. The company saw a 6.6% year-over-year revenue increase to $15.42 billion, and institutional investors collectively own 70.23% of its stock.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-yousif-capital-management-llc-sells-5410-shares-of-abbvie-inc-abbv-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T095444",
      "overall_sentiment_score": 0.072229,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.108536,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.38912
    },
    {
      "title": "Astrazeneca bows to Donald Trump and slashes US drug prices by up to 80%",
      "summary": "AstraZeneca has announced it will cut drug prices in the US by up to 80% and offer direct-to-consumer sales for eligible patients with chronic conditions. This move is in response to pressure from former President Donald Trump to reduce medication costs and aims to avoid potential tariffs. The company also plans to invest up to $50bn in US manufacturing and R&D over the next five years, signaling a strategic shift towards the US market.",
      "url": "https://www.business-live.co.uk/enterprise/astrazeneca-bows-donald-trump-slashes-32665867.amp",
      "source": "business-live.co.uk",
      "published": "20251013T123700",
      "overall_sentiment_score": 0.1257,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.103224,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.349863
    },
    {
      "title": "Concord Asset Management LLC VA Purchases 1,691 Shares of AbbVie Inc. $ABBV - MarketBeat",
      "summary": "Concord Asset Management LLC VA increased its stake in AbbVie Inc. by 27.9% in the second quarter, bringing its total holdings to 7,759 shares valued at $1.44 million. Other institutional investors also adjusted their positions in the pharmaceutical company. Wall Street analysts have provided positive outlooks for AbbVie, with increased price targets, as the company reported its quarterly earnings and declared a dividend.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-concord-asset-management-llc-va-purchases-1691-shares-of-abbvie-inc-abbv-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T093636",
      "overall_sentiment_score": 0.345374,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.319751,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.348152
    },
    {
      "title": "Procter & Gamble: A Century of Steady Gains in the Dow Jones - Disruption Banking",
      "summary": "This article traces Procter & Gamble's journey from its origins to its perennial status as a stable Dow Jones component, highlighting its resilience through economic downturns and consistent growth. It details P&G's strategic evolution, financial performance in 2025, and brand power, alongside recent analyst ratings. The piece emphasizes P&G’s enduring role as a reliable anchor in the Dow Jones Industrial Average.",
      "url": "https://www.disruptionbanking.com/2025/10/13/procter-gamble-a-century-of-steady-gains-in-the-dow-jones/",
      "source": "Disruption Banking",
      "published": "20251013T142818",
      "overall_sentiment_score": 0.179247,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.111896,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.344955
    },
    {
      "title": "Procter & Gamble Sold by Large Institution After Lagging S&P 500 This Year. Should Investors Buy on the Dip?",
      "summary": "Sunflower Bank, N.A. sold a significant portion of its Procter & Gamble (P&G) shares, valued at approximately $16.56 million, during Q3 2025 after P&G underperformed the S&P 500. Despite this institutional sell-off, the article suggests that value-oriented investors might consider buying P&G stock due to its elevated dividend yield and potential catalysts such as CEO succession, ongoing restructuring, and new product collaborations. The stock's recent underperformance could present a dip-buying opportunity for long-term investors.",
      "url": "https://www.fool.com/coverage/filings/2025/10/13/procter-and-gamble-sold-by-large-institution-after-lagging-s-and-p-500-this-year-should-investors-buy-on-the-dip/",
      "source": "The Motley Fool",
      "published": "20251013T214410",
      "overall_sentiment_score": 0.165569,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.145759,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.341557
    },
    {
      "title": "Novo Nordisk update raises questions on Repligen approval, says Canaccord - TipRanks",
      "summary": "Canaccord highlights that Novo Nordisk's update regarding Catalent's facility and its \"Official Action Indicated\" classification could delay approval for Regeneron's EYLEA HD prefilled syringe, which is manufactured at the same site. Despite this, the firm maintains a Buy rating and an $850 price target for Regeneron. Canaccord also suggests that upcoming data on Novo's semaglutide in Alzheimer's could benefit Regeneron's related muscle-sparing programs and potentially lead to combination therapies.",
      "url": "https://www.tipranks.com/news/the-fly/novo-nordisk-update-raises-questions-on-repligen-approval-says-canaccord-thefly",
      "source": "TipRanks",
      "published": "20251013T144419",
      "overall_sentiment_score": 0.07741,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": -0.14051,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.331107
    },
    {
      "title": "Johnson & Johnson (JNJ) call put ratio 1 call to 1 put into quarter results - StreetInsider",
      "summary": "Johnson & Johnson (JNJ) is showing an October call option implied volatility of 37 and a November implied volatility of 22, compared to its 52-week range of 13 to 35. Leading up to its quarterly results release on October 14, the call-put ratio for JNJ stands at 1 call to 1 put. The company's stock is currently priced at $190.37 with a market rating of SELL and a dividend yield of 2.9%.",
      "url": "https://www.streetinsider.com/Option+EPS+Action/Johnson+%26+Johnson+%28JNJ%29+call+put+ratio+1+call+to+1+put+into+quarter+results/25447946.html",
      "source": "StreetInsider",
      "published": "20251013T150907",
      "overall_sentiment_score": 0.049901,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.002994,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.329873
    },
    {
      "title": "Oregon Public Employees Retirement Fund Raises Stake in AbbVie Inc. $ABBV",
      "summary": "The Oregon Public Employees Retirement Fund increased its stake in AbbVie Inc. (NYSE:ABBV) by 0.7% in the second quarter, bringing its total holdings to 152,736 shares valued at $28.35 million. This makes AbbVie the fund's 24th largest position. Several other institutional investors also adjusted their holdings in AbbVie, which currently has a market capitalization of $407.86 billion and a \"Moderate Buy\" consensus rating from analysts.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-oregon-public-employees-retirement-fund-raises-stake-in-abbvie-inc-abbv-2025-10-13/",
      "source": "MarketBeat",
      "published": "20251013T093636",
      "overall_sentiment_score": 0.168538,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.139111,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.32905
    },
    {
      "title": "SM ENERGY SCHEDULES THIRD QUARTER 2025 EARNINGS RELEASE AND LIVE Q&A CALL - StreetInsider",
      "summary": "SM Energy Company (NYSE: SM) announced its schedule for releasing third-quarter 2025 financial and operating results. The company plans to issue its results, including an earnings release, pre-recorded webcast, and presentation, after market hours on November 4, 2025. A live Q&A session with SM Energy management will follow on November 5, 2025, at 8:00 a.m. Mountain time/10:00 a.m. Eastern time.",
      "url": "https://www.streetinsider.com/PRNewswire/SM+ENERGY+SCHEDULES+THIRD+QUARTER+2025+EARNINGS+RELEASE+AND+LIVE+Q%26amp%3BA+CALL/25448358.html",
      "source": "StreetInsider",
      "published": "20251013T201820",
      "overall_sentiment_score": 0.016367,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.023327,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.314632
    }
  ]
}